Navigation Links
Velocity Pharmaceutical Development and Tigercat Pharma Inc. Announce Submission of IND Application for VPD-737
Date:8/19/2013

SOUTH SAN FRANCISCO, Calif., Aug. 19, 2013 /PRNewswire/ -- Velocity Pharmaceutical Development, LLC ("VPD") and Tigercat Pharma, Inc., ("Tigercat") announced today the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for VPD-737 for the treatment of chronic pruritus.

Tigercat licensed worldwide rights to VPD-737 (Serlopitant), an NK-1 receptor antagonist, from Merck (Essex Chemie) in 2012.  Tigercat intends to develop VPD-737 through clinical proof of concept for the treatment of chronic pruritus, defined as itch lasting for more than 6 weeks. This condition results in more than one million doctor visits per year in the US. Chronic pruritus is associated with significant morbidity and can result in serious disruption of sleep and other activities of daily living.

"Preclinical studies and compelling clinical evidence about the use of NK-1 receptor antagonists led us to believe that treatment with VPD-737 may significantly and rapidly reduce pruritus associated with a variety of conditions" said David Collier, CEO of VPD. "We believe this drug has the potential to address a major underappreciated medical need."

Jean Tang M.D., Ph.D., Professor of Dermatology at Stanford University School of Medicine said "Chronic itch is a largely underserved indication with few effective treatments.  The existing drugs to treat chronic itch are at best only modestly effective and in addition, they are poorly tolerated. Thus we are very excited to see VPD-737 approaching clinical testing."

About Tigercat Pharma, Inc.
Tigercat Pharma, Inc., is a largely "virtual" company which was created to hold the ownership of the VPD-737 development program.  Tigercat is funded by Velocity Pharmaceutical Holdings, LLC, and Remeditex Ventures, LLC.  The VPD-737 development program is managed
'/>"/>

SOURCE Velocity Pharmaceutical Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmaceutical Cold Supply Chain and Green Logistics, a New Xtalks Life Sciences Webinar
2. Intercept Pharmaceuticals Reports Second Quarter 2013 Financial Results
3. Pharmaceutical Companies Announce Quarterly Financial Results - Research Report on Jazz, Acadia, Arena, Santarus, and Incyte
4. GW Pharmaceuticals to Present at the 33rd Annual Canaccord Genuity Growth Conference
5. James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
6. Flagship Biosciences Expands Digital Pathology with Pharmaceutical Biostatistics Services
7. India Pharmaceutical Sector Reviewed by Kelly Scientific Publications in In-demand Report Now Available at MarketPublishers.com
8. Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
9. PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
10. RXi Pharmaceuticals Announces Application for NASDAQ Capital Market Listing and Reverse Stock Split
11. China Pharmaceutical Industry Examined in New Kelly Scientific Publications Report Available at MarketPublishers.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Lighthouse Information Systems, Inc., a ... California, Oregon, Washington and clients across the US, ... Acquisition (M&A) Integration Services offering, effective immediately. ... and M&A Integration Practice Leader at Lighthouse, explains, ... of M&A initiatives fail to achieve their intended ...
(Date:3/30/2015)... & Struggles (Nasdaq: HSII ), the premier provider of ... culture shaping worldwide, today  announced that John Mitchell ... and Life Sciences practice. As Global Practice Managing ... team of more than 80 partners, principals and associates in ... Asia serving clients in the biopharmaceutical, medical technology ...
(Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a commercial focus on ... and Drug Administration (CFDA) has approved the Company,s application ... ovarian clear cell carcinoma (OCCC) patients for its proprietary ...
(Date:3/30/2015)... USA (PRWEB) March 29, 2015 A ... the United States and plenary talks by four leading ... SPIE Optics + Optoelectronics next month in Prague, ... presentations in 17 conferences alongside a two-day exhibition. Sponsored ... photonics , the event will run 13-16 April in ...
Breaking Biology Technology:Lighthouse Information Systems, Inc., Announces Addition of M&A Integration Services 2Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3
... a ground-breaking assembly that has the potential to impact ... and optical materials. The work, reported in ... was conducted by researchers at New York University,s Department ... University of Milan,s Department of Materials Science. Researchers ...
... America,s #1 rated morning news program, The Today Show ... test that measures cellular aging.  The segment entitled How ... a tool for those interested in monitoring their health with ... a person,s biological age in comparison to their chronological age, ...
... ViroPharma Incorporated,s (Nasdaq: VPHM ) second quarter ... Thursday, July 28, 2011 before the open of the U.S. ... call and live audio webcast at 9:00 a.m. Eastern Time ... will discuss the 2011 second quarter financial results and other ...
Cached Biology Technology:Chemists create molecular polyhedron -- and potential to enhance industrial and consumer products 2SpectraCell's Telomere Testing Goes Mainstream 2SpectraCell's Telomere Testing Goes Mainstream 3ViroPharma to Release 2011 Second Quarter Financial Results on July 28, 2011 2
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report to ... for Hand Geometry in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and ...
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/12/2015)... -- The mascots of the Atlantic Coast Conference spent ... Forest Baptist Medical Center. They stopped by as part ... Basketball Tournament. Young patients enjoyed bonding with their favorite ... Brenner Children,s Hospital is the pediatric arm ... hospital in northwest North Carolina ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... majority of orchids are found in habitats where light ... is not surprising that many achlorophyllous (lacking chlorophyll), as ... symbionts to supply them with carbohydrates in order to ... of habitats and range in their photosynthetic capabilities. ...
... Research to be presented at the upcoming annual meeting of ... foremost society for research into all aspects of eating and ... increases our willingness to pay for food, while simultaneously decreasing ... ever wondered about why you are willing to pay more ...
... instructions for developing limbs and digits were present in ... crawled on to land, researchers have discovered. Genetic ... When a particular switch taken from fish DNA is ... in the developing limb region of embryos, University of ...
Cached Biology News:Orchids and fungi: An unexpected case of symbiosis 2Orchids and fungi: An unexpected case of symbiosis 3Orchids and fungi: An unexpected case of symbiosis 4Genetic switch for limbs and digits found in ancient fish 2Genetic switch for limbs and digits found in ancient fish 3
... Kit provides a unique signal amplification technology ... including cell-surface receptors and subcellular structures. The ... patented ELF 97 phosphatase substrate, which yields ... site of enzymatic activity a process ...
... C 4 H 10 O ... 154.25 PRODUCT SPECIFICATIONS Form: White crystalline ... to 97% Identity: By IR Melting ... 38C Oxidized DTT: less than or ...
... The Fluorescence Test Plate consists of ... format, with Inert Organic Fluorescent Compounds embedded ... be used on BioTeks FLx800 and Synergy ... ideal for GLP compliance while reducing the ...
... excellent performance with isocratic IC methods. ... column heater all standard, this compact, ... stability. The vacuum degas option delivers ... Operate in manual or automated mode ...
Biology Products: